SMT202400417T1 - Derivati di n-(imidazo[1,2-b]piridazin-3-il)-1-cicloesil-2h-indazol-5-carbossammide e n-(pirazol[1,5-a]pirimidin-3-il)-1-cicloesil-2h-indazol-5-carbossammide come inibitori di irak4 per il trattamento di asma - Google Patents

Derivati di n-(imidazo[1,2-b]piridazin-3-il)-1-cicloesil-2h-indazol-5-carbossammide e n-(pirazol[1,5-a]pirimidin-3-il)-1-cicloesil-2h-indazol-5-carbossammide come inibitori di irak4 per il trattamento di asma

Info

Publication number
SMT202400417T1
SMT202400417T1 SM20240417T SMT202400417T SMT202400417T1 SM T202400417 T1 SMT202400417 T1 SM T202400417T1 SM 20240417 T SM20240417 T SM 20240417T SM T202400417 T SMT202400417 T SM T202400417T SM T202400417 T1 SMT202400417 T1 SM T202400417T1
Authority
SM
San Marino
Prior art keywords
indazole
cyclohexyl
carboxamide
pyridazin
pyrazolo
Prior art date
Application number
SM20240417T
Other languages
English (en)
Italian (it)
Inventor
Ina Terstiege
Stefan Schiesser
Yafeng Xue
Hui-Fang Chang
Anna Ingrid Kristina Berggren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SMT202400417T1 publication Critical patent/SMT202400417T1/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM20240417T 2020-12-10 2021-12-09 Derivati di n-(imidazo[1,2-b]piridazin-3-il)-1-cicloesil-2h-indazol-5-carbossammide e n-(pirazol[1,5-a]pirimidin-3-il)-1-cicloesil-2h-indazol-5-carbossammide come inibitori di irak4 per il trattamento di asma SMT202400417T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063199160P 2020-12-10 2020-12-10
PCT/EP2021/084916 WO2022122876A1 (en) 2020-12-10 2021-12-09 N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma
EP21836097.2A EP4259632B1 (en) 2020-12-10 2021-12-09 N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma

Publications (1)

Publication Number Publication Date
SMT202400417T1 true SMT202400417T1 (it) 2024-11-15

Family

ID=79230946

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240417T SMT202400417T1 (it) 2020-12-10 2021-12-09 Derivati di n-(imidazo[1,2-b]piridazin-3-il)-1-cicloesil-2h-indazol-5-carbossammide e n-(pirazol[1,5-a]pirimidin-3-il)-1-cicloesil-2h-indazol-5-carbossammide come inibitori di irak4 per il trattamento di asma

Country Status (33)

Country Link
US (3) US11866405B2 (enExample)
EP (1) EP4259632B1 (enExample)
JP (1) JP7749015B2 (enExample)
KR (1) KR20230118153A (enExample)
CN (1) CN116583285B (enExample)
AR (1) AR124303A1 (enExample)
AU (1) AU2021395816B2 (enExample)
CA (1) CA3203569A1 (enExample)
CL (1) CL2023001662A1 (enExample)
CO (1) CO2023007624A2 (enExample)
CR (1) CR20230264A (enExample)
DK (1) DK4259632T3 (enExample)
DO (1) DOP2023000119A (enExample)
EC (1) ECSP23050553A (enExample)
ES (1) ES2989489T3 (enExample)
FI (1) FI4259632T3 (enExample)
HR (1) HRP20241312T1 (enExample)
HU (1) HUE068584T2 (enExample)
IL (1) IL303356B1 (enExample)
LT (1) LT4259632T (enExample)
MA (1) MA62535B1 (enExample)
MX (1) MX2023006816A (enExample)
PE (1) PE20240684A1 (enExample)
PL (1) PL4259632T3 (enExample)
PT (1) PT4259632T (enExample)
RS (1) RS66095B1 (enExample)
SI (1) SI4259632T1 (enExample)
SM (1) SMT202400417T1 (enExample)
TW (1) TWI902994B (enExample)
UA (1) UA130417C2 (enExample)
UY (1) UY39561A (enExample)
WO (1) WO2022122876A1 (enExample)
ZA (1) ZA202306848B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7555519B2 (ja) * 2022-02-14 2024-09-24 アストラゼネカ・アクチエボラーグ Irak4阻害剤
US20250326757A1 (en) * 2022-05-26 2025-10-23 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors
TW202508568A (zh) 2023-04-07 2025-03-01 瑞典商阿斯特捷利康公司 Irak4蛋白水解靶向嵌合體

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003219A (zh) 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
BG111378A (bg) * 2013-01-14 2015-01-30 Николай Цветков Субституирани индазолови производни като in-vitro mao-b инхибитори
DK2970139T3 (en) 2013-03-15 2018-08-13 Biomarin Pharm Inc HDAC inhibitors
EP3092226B1 (en) 2014-01-10 2019-03-13 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Irak4抑制劑組合
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
JP2018524372A (ja) 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Irak−4阻害剤としてのインダゾール及びアザインダゾール化合物
CN105503863A (zh) * 2015-12-11 2016-04-20 南京华威医药科技开发有限公司 新型抗肿瘤化合物
CN108473498B (zh) 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
EP3642201A1 (en) 2017-06-21 2020-04-29 H. Hoffnabb-La Roche Ag Isoindolinone derivatives as irak4 modulators
JP2020524692A (ja) 2017-06-21 2020-08-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Irak4調節因子としてのベンゾフラン
US20230002361A1 (en) 2019-06-27 2023-01-05 Biogen Ma Inc. 2h-indazole derivatives and their use in the treatment of disease
JP7576581B2 (ja) 2019-06-27 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるそれらの使用

Also Published As

Publication number Publication date
US20240182479A1 (en) 2024-06-06
ECSP23050553A (es) 2023-08-31
TWI902994B (zh) 2025-11-01
EP4259632A1 (en) 2023-10-18
CN116583285B (zh) 2026-03-24
PL4259632T3 (pl) 2024-12-16
PE20240684A1 (es) 2024-04-10
UA130417C2 (uk) 2026-02-11
US20260092069A1 (en) 2026-04-02
IL303356B1 (en) 2026-04-01
AU2021395816B2 (en) 2024-04-04
US20220185817A1 (en) 2022-06-16
MA62535B1 (fr) 2024-11-29
LT4259632T (lt) 2024-10-10
IL303356A (en) 2023-08-01
WO2022122876A1 (en) 2022-06-16
HUE068584T2 (hu) 2025-01-28
HRP20241312T1 (hr) 2024-12-20
AR124303A1 (es) 2023-03-15
US12448385B2 (en) 2025-10-21
UY39561A (es) 2022-06-30
CO2023007624A2 (es) 2023-06-30
DK4259632T3 (da) 2024-10-21
MX2023006816A (es) 2023-06-21
KR20230118153A (ko) 2023-08-10
EP4259632B1 (en) 2024-07-24
DOP2023000119A (es) 2023-07-09
CR20230264A (es) 2023-07-26
AU2021395816A1 (en) 2023-07-13
ZA202306848B (en) 2024-04-24
CA3203569A1 (en) 2022-06-16
FI4259632T3 (fi) 2024-10-24
JP7749015B2 (ja) 2025-10-03
RS66095B1 (sr) 2024-11-29
TW202237612A (zh) 2022-10-01
CN116583285A (zh) 2023-08-11
CL2023001662A1 (es) 2024-01-12
JP2023552838A (ja) 2023-12-19
US11866405B2 (en) 2024-01-09
SI4259632T1 (sl) 2024-12-31
PT4259632T (pt) 2024-10-24
AU2021395816A9 (en) 2025-03-13
ES2989489T3 (es) 2024-11-26

Similar Documents

Publication Publication Date Title
PT4259632T (pt) Derivados de n-(imidazo[1,2-b]piridazin-3-il)-1- ciclohexil-2h-indazol-5-carboxamida e n-(pirazolo[1,5- a]pirimidina-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inibidores de irak4 para o tratamento da asma
RU2412171C2 (ru) Новое соединение пиперазина и его применение в качестве ингибитора hcv полимеразы
CA3266687A1 (en) PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR CANCER TREATMENT
NZ599291A (en) Antimicrobial compounds and methods of making and using the same
MY146474A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
NZ623922A (en) Novel tricyclic compounds
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
IL186422A0 (en) Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
WO2007039740A3 (en) Preparation and use of tetrahydropyrrolo [3, 2-c] pyridin-4-one derivatives for treatment of obesity, psychiatric and neurological disorders
PT1948654E (pt) Derivados da 5-amino-4-hidroxi-7-(imidazo[1,2-a] piridin-6-ilmetil)-8-metil-nonamida e compostos relacionados como inibidores da renina para o tratamento da hipertensão
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.
EP3856743A4 (en) SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
IL272652B (en) A pentacyclic compound, the pharmaceutical compounds that make it up and their use for the treatment of Alzheimer's disease
MX362197B (es) Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
ZA202102974B (en) 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
EP4393924A4 (en) IMIDAZO[1,2-A]PYRAZINE OR PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVE AND USE THEREOF
MX2023005761A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
HK40103397A (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use
WO2006127574A3 (en) Method for the treatment of noise phobia in companion animals
HK40116553A (en) Polymorphic and salt forms of (ls,3s)-n-(5-(pentan-3-yl)pyrazolo[l,5-a]pyrimidin-7-yl)cyclopentane-l,3-diamine
HK40102603A (en) Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease
AU2023904024A0 (en) Use of selected (1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone compounds in the treatment of cardiovascular diseases
WO2024073282A3 (en) Heterocycles as modulators of nsd activity
HK40120391A (en) Pharmaceutically acceptable salt and polymorph of substituted pyrazolo[1,5-a]pyrimidin-7-amine derivative and use thereof